Immune cells take aim at Post-Transplant virus

NCT ID NCT07438067

Recruiting now Disease control Sponsor: Daihong Liu Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This early-stage study tests a new treatment using specially grown immune cells (EBV-AST cells) to fight EBV infections in people who have had a stem cell transplant. The trial will enroll 18 adults with persistent EBV in their blood. Researchers will test three different doses to find the safest and most effective one, while also monitoring how well the cells clear the virus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EBV-specific immune cells (EBV-AST cells)
What this could lead to: If it works, this could offer a targeted way to control EBV infections after stem cell transplants, reducing the risk of serious complications like post-transplant lymphoma.
What could go wrong: This is a very early, small study (18 people) focused on safety and dosing. The treatment may not work, and there are risks like infusion reactions or graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBV-DNA VIREMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

post-transplant lymphoproliferative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EBV-DNA VIREMIA POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER

Contacts and locations

Locations

Chinese PLA General Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.